Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma

NCT00118274 is registered in ClinicalTrials.gov with Craig L Slingluff, Jr as lead sponsor.

NCT NCT00118274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00118274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Lead sponsor
Craig L Slingluff, Jr
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2005
Completion date
February 28, 2010
Enrollment
170 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)